XOMA — Xoma Royalty Share News
0.000.00%
Last trade - 00:00- $792.01m
- $808.75m
- $52.15m
Brief: Xoma-Non-Dilutive, Non-Recourse, Royalty-Backed Loan For Up To $140 Million Of Capital
Brief: Xoma - One New Drug Application Was Filed In Q3 Another Anticipated Prior To Year-End
Brief: XOMA Earns $5 Million Milestone Upon FDA Acceptance Of Day One’s Tovorafenib NDA For Relapsed Or Progressive Pediatric Low-Grade Glioma (PLGG)
Xoma Corp Expected To Post A Loss Of 48 Cents A Share: Earnings Preview
Brief: Xoma Corp Will Seek To Out-License Ebopiprant For Further Development
Brief: XOMA Says On Sept 11, 2023, Co Received $4.9 Mln Commercial Payment From Genentech, Stemming From Sales Of VABYSMO During First 6 Months Of 2023
Brief: Xoma Corp says Novartis Pharma AG Communicated To Co, It Intends To Discontinue Development Activities Related To Nis793
Xoma Corp Reports Results For The Quarter Ended In June: Earnings Summary
Brief: XOMA Reports Second Quarter 2023 Financial Results
Brief: XOMA Corporation Q2 Revenue USD 1.7 Mln
Xoma Corp Expected To Post A Loss Of 52 Cents A Share: Earnings Preview
Brief: Xoma Corp Novartis International Pharma Discontinuing Phase 3 Trial Investigating NIS793
XOMA Corp rises on acquiring assets royalty, milestone rights from LadRx
Brief: Xoma Acquires Royalty And Milestone Economics To Phase 3 First-In-Class Orphan Disease Asset For Niemann-Pick Disease Type C And Phase 2 Oncology Asset
Xoma Corp Reports Results For The Quarter Ended In March: Earnings Summary
Brief: XOMA Reports First Quarter 2023 Financial Results
Xoma Corp Expected To Post A Loss Of 50 Cents A Share: Earnings Preview
Brief: Xoma Acquires Cashflow-Generating Asset For Its Royalty And Milestone Portfolio
Brief: Xoma Corp - On March 21, 2023, Received Adverse Decision In Arbitration Proceeding With Licensees